" />
Skip to main content
Sign In

Blood Cancer and BMT Program
 

Current Clinical Trials


 

 For more information click the study identifier or search the identifier number at clinicaltrials.gov

 

 Acute Lymphoblastic Leukemia (non transplant)

ClinicalTrials.gov
Identifier
Study Title ​Study Coordinator
NCT01564784 Pfizer B1931022: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia (ALL)

​Emily Denoncourt
720-848-0566

NCT01132573 A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995, IND#61198) plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in Adults with Relapsed and Refractory Disease ​Nicole Adler
720-848-0678
1

 Acute Myeloid Leukemia (non-transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NCT01358734 A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Group Study of A Lenalidomide (Revlimid®) Regimen or A Sequential Azacitidine (Vidaza®) plus Lenalidomide (Revlimid®) Regimen Versus Azacitidine (Vidaza®) Regimen for Therapy of Older Subjects with Newly Diagnosed Acute Myeloid Leukemia ​Leigh Walzer
720-848-0736
NCT01743859 Celgene RV-AML-PI - 0759: Sequential Treatment with Azacitidine and Lenalidomide for Relapsed and Refractory Patients with Acute Myeloid Leukemia Leigh Walzer
720-848-0736​
NCT01546038 A Phase 1B/2 Study to Evaluate the Safety and Preliminary Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-c, or Decitabine in Patients with Acute Myeloid Leukemia or High Risk Myelodyplastic Syndrome ​Leigh Walzer
720-848-0736
NCT00840177 ​S0919, A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia (AML) ​Leigh Walzer
720-848-0736​
NCT01915498 ​A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation. ​Nichole Adler 720-848-0678
Derek Schatz 720-8480628
NCT01994837         A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML)
​​10

 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (non transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NCT01886859 A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ​Nicole Adler
720-848-0678
2

 Hodgkin Lymphoma (non transplant)

No current trials recruiting3

 Myelodysplastic Syndrome (non transplant)

ClinicalTrials.gov
Identifier
Study Title Study Coordinator​
NCT01522976 SWOG S1117: A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-7036813) versus Azacitidine Alone versus Azacitidine in Combination with Vorinostat (NSC - 701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) ​Leigh Walzer
720-848-0736
NCT01546038 A Phase 1B/2 Study to Evaluate the Safety and Preliminary Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-c, or Decitabine in Patients with Acute Myeloid Leukemia or High Risk Myelodyplastic Syndrome ​Leigh Walzer
720-848-0736
NCT01584531 ​A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification ​Nikki Ayodeji
720-848-0701
​​NCT01915498 ​A Phase I, Multicenter, Open-Label, Dose-Escalationa, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation ​Nichole Adler
720-848-0678
4

 Myeloma (non transplant)

ClinicalTrials.gov Identifier Study Title Study Coordinator
NCT01734928 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone versus Bortezomib and Low-Dose Dexamethasone in subjects with Relapsed and Refractory Multiple Myeloma 

Leigh Walzer, 720-848-0736

NCT01989325​ ​A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple Myeloma ​Derek Schatz, 720-848-0628
5

 Non Hodgkin Lymphoma: Follicular & other indolent (non transplant)

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator
NCT01294579 A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non- Hodgkin’s Lymphoma (B-NHL) Which Has Relapsed after Rituximab or a Rituximab-Containing Therapy ​Leigh Walzer
720-848-0736
6

 Non Hodgkin Lymphoma: Mantle Cell (non transplant)

​No current trials recruiting7

 Non Hodgkin Lymphoma: DLBCL and other aggressive (non transplant)

​No current trials recruiting8

 Transplant

ClinicalTrials.Gov
Identifier
Study Title Study Coordinator​
NCT00723099 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen ​Derek Schatz
720-848-0628
NCT01231412 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial ​​Derek Schatz
720-848-0628
NCT01690520 ​Multi-center, open-label randomized study of single or double myeloablative cord blood transplantation with or without infusion of off-the-shelf ex vivo expanded cryopreserved cord blood progenitor cells in patients with hematologic malignancies ​​Derek Schatz
720-848-0628
​NCT01841333 ​A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse ​​Emily Denoncourt
720-848-0566
NCT01610414 ​GSK 115523: A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01B candidate vaccine when administered intramuscularly on a two-dose schedule to adult autologous haematopoietic stem cell transplant (HCT) recipients. ​​Derek Schatz
720-848-0628
NCT01769170 ​Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematolpoietic Stem Cell Transplant Recipients ​Derek Schatz
720-848-0628
9